Lite Strategy, INC. (LITS) — 8-K Filings

All 8-K filings from Lite Strategy, INC.. Browse 23 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (23)

Lite Strategy Inc. Announces Director Changes — Dec 30, 2025 Risk: medium
Lite Strategy, Inc. (formerly MEI Pharma, Inc.) announced on December 23, 2025, the departure of Director Dr. Brian J. Fox and the appointment of Dr. David E. J
Lite Strategy, Inc. Changes Certifying Accountant — Dec 5, 2025 Risk: medium
Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on December 5, 2025, reporting a change in its certifying accountant. The company, located at 9920
Lite Strategy, Inc. Reports Board and Officer Changes — Nov 18, 2025 Risk: medium
Lite Strategy, Inc. announced on November 14, 2025, changes related to its board of directors and officers, including the departure of certain individuals and t
Lite Strategy Inc. Announces Director Changes and Officer Compensation — Oct 30, 2025 Risk: low
Lite Strategy, Inc. announced on October 24, 2025, the departure of Director Dr. David E. Johnson and the appointment of Dr. Jonathan M. Roth as a new director.
Lite Strategy, Inc. Reports Unregistered Equity Sales — Sep 15, 2025 Risk: medium
Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on September 15, 2025, reporting unregistered sales of equity securities on September 10, 2025. The
MEI Pharma Files 8-K with Corporate Updates — Sep 10, 2025 Risk: low
MEI Pharma, Inc. filed an 8-K on September 10, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial
MEI Pharma Enters Material Definitive Agreement — Sep 4, 2025 Risk: medium
MEI Pharma, Inc. announced on September 3, 2025, the entry into a material definitive agreement. This filing also indicates the creation of a direct financial o
MEI Pharma Appoints New CFO and Directors — Aug 6, 2025 Risk: medium
MEI Pharma, Inc. announced on August 5, 2025, changes in its board and executive team. The company elected two new directors, Dr. David E. Johnson and Ms. Karen
MEI Pharma Files 8-K with Financials and Other Events — Aug 5, 2025 Risk: low
MEI Pharma, Inc. filed an 8-K on August 5, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as w
MEI Pharma Reports Unregistered Equity Sale — Jul 30, 2025 Risk: medium
MEI Pharma, Inc. announced on July 24, 2025, an unregistered sale of equity securities. The company, incorporated in Delaware, filed this Form 8-K to report thi
MEI Pharma Announces Material Agreement Termination & Officer Changes — Jul 22, 2025 Risk: medium
MEI Pharma, Inc. announced on July 17, 2025, the termination of a material definitive agreement. The company also reported on unregistered sales of equity secur
MEI Pharma Announces CMO Departure, Director Changes — Mar 7, 2025 Risk: medium
MEI Pharma, Inc. announced on March 3, 2025, the departure of Dr. Brian D. D. Smith from his role as Chief Medical Officer. The company also reported on the ele
MEI Pharma Files 8-K on Shareholder Vote Matters — Jan 31, 2025 Risk: low
MEI Pharma, Inc. filed an 8-K on January 31, 2025, reporting on matters submitted to a vote of security holders as of January 30, 2025. The filing details the c
MEI Pharma Files 8-K on Shareholder Nominations — Nov 25, 2024 Risk: medium
MEI Pharma, Inc. filed an 8-K on November 25, 2024, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the report is
MEI Pharma Files 8-K on Financials — Nov 14, 2024 Risk: low
MEI Pharma, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition as of November 12, 2024. The filing includes
MEI Pharma Acquired by PharmaEssentia — Oct 25, 2024 Risk: medium
MEI Pharma, Inc. announced on October 22, 2024, the completion of its acquisition by PharmaEssentia Corporation. The transaction involved the acquisition of all
MEI Pharma Announces Board Changes and New CMO — Aug 2, 2024 Risk: medium
MEI Pharma, Inc. announced on July 31, 2024, a series of significant corporate changes. These include the departure of Director Kevin R. Lind, the election of n
MEI Pharma Files 8-K: Regulation FD & Exhibits — Jul 30, 2024 Risk: low
On July 30, 2024, MEI Pharma, Inc. filed an 8-K report to disclose information regarding a Regulation FD Disclosure and Financial Statements and Exhibits. The f
PharmaEssentia to Acquire MEI Pharma for $416M — Jul 22, 2024 Risk: medium
MEI Pharma, Inc. announced on July 21, 2024, that it has entered into a definitive agreement to be acquired by PharmaEssentia Corporation for approximately $3.0
MEI Pharma Appoints New Chief Medical Officer — Jun 25, 2024 Risk: medium
On June 18, 2024, MEI Pharma, Inc. announced the appointment of Dr. Brian A. Fox as Chief Medical Officer. Dr. Fox brings extensive experience in oncology drug
MEI Pharma Files 8-K for Disclosure and Exhibits — May 21, 2024 Risk: low
MEI Pharma, Inc. filed an 8-K on May 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
MEI Pharma Files Standard 8-K Report — Feb 21, 2024 Risk: low
MEI Pharma, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing is a standard current report under Section
MEI Pharma 8-K: Officer/Director Changes, Comp Arrangements — Jan 17, 2024
MEI Pharma, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024, related to changes in its directors or officers and the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX